EWM
CPRX

Evermay Wealth Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Evermay Wealth Management’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$315 Buy
+10
New +$295 ﹤0.01% 634

Other funds holding CPRX

Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
CIEC
Crédit Industriel et Commercial Paris France, France $1.55B AUM 42.08% 1-Year Est. Return
LTAS
Linden Thomas Advisory Services Charlotte, North Carolina $1.24B AUM 47.37% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return
COPPSERS
Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return
CWP
Cyndeo Wealth Partners St. Petersburg, Florida $2.12B AUM 24.61% 1-Year Est. Return
AA
ABC Arbitrage Paris, France $926M AUM 45.9% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
CNAM
Campbell Newman Asset Management Milwaukee, Wisconsin $1.35B AUM 38.87% 1-Year Est. Return
CCM
Chicago Capital Management Chicago, Illinois $112M AUM 76.54% 1-Year Est. Return

Evermay Wealth Management's CPRX Position: Q2 2026 in Review

Evermay Wealth Management opened a new position in Catalyst Pharmaceutical (CPRX) in Q2 2026: 10 shares worth $315. The stake represents ﹤0.01% of the portfolio and ranks #634 among its holdings.

87 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

  • Evermay Wealth Management held 10 shares of Catalyst Pharmaceutical worth $315 as of Q2 2026.
  • Catalyst Pharmaceutical was a new Evermay Wealth Management position in Q2 2026.
  • Catalyst Pharmaceutical made up ﹤0.01% of Evermay Wealth Management's portfolio in Q2 2026, its #634 holding.
  • 87 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Evermay Wealth Management's 13F filing for Q2 2026, filed 27 Jul 2026.